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Cortisol, phenylbutazone, indomethacin, acetylsalicylic acid, meclofena- 
mic acid, flufenamic acid and mefanamic acid were potent inhibitors of 
connective tissue activation, especially if introduced into synovial cultures 
within 2 hours of initiation of the activation process. Colchicine, chloro- 
quine and gold thiomalate were ineffective, while hydroxychloroquine and 
sodium salicylate exhibited modest inhibitory capacity. Most of the active 
agents exhibited suppressive capacity at concentrations similar to those 
used clinically. The suppressive capacity of the various drugs was reduced 
20 to 60% by the presence of serum. Antirheumatic drugs do not appear to  
alter the activity of the stimulatory connective tissue activating peptide 
molecule itself, but may act by interfering with the transcriptional and 
translational components of the connective tissue activation sequence. 
Development of rational therapy to interdict 
self-perpetuating, destructive inflammatory 
processes will require precise knowledge of the 
interlocking components of these phenomena. 
The clotting process, kinin generation, activa- 
tion of the complement sequence, release of ly- 
sosomal enzymes and phagocytic activity are 
interwoven in a complex and poorly understood 
manner. Most of these component processes are 
incompletely understood in themselves, and 
their reacting constituents are only partially 
characterized in chemical terms. Little critical 
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information exists concerning the factors regu- 
lating the interaction of these interlocking sys- 
tems, and even the relative importance of the 
components listed is not clear. Conventional 
views of inflammation suggest that acute (exu- 
dative) phenomena primarily embrace altered 
behavior of the microcirculatory system, in- 
cluding the vascular endothelium itself, leu- 
kocytes, platelets and soluble plasma constitu- 
ents. Reparative phenomena derive from the 
activity of connective tissue cells and occur later 
in the inflammatory process when formation of 
glycosaminoglycans and collagen is detected. 
This laboratory reported a polypeptide which 
may function to initiate the transition from the 
exudative to the reparative phase of the 
inflammatory process (1). This activator poly- 
peptide (CTAP) is derivable from exudative 
cells (2, 3) and induces hypermetabolic activity 
in synovial cells, including markedly increased 
glycolysis and accelerated formation of hyalu- 
ronic acid (1, 3), a process we have termed 
$ <  connective tissue activation.” Recently, it has 
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been shown that the peak of CTAP activity in 
cotton pellet granulomata occurs early, when 
the transition from the acute to the reparative 
stage of this inflammatory reaction is seen 
microscopically (4). While chronic, self-per- 
petuating inflammation clearly involves con- 
tinuation of  both the exudative and reparative 
phases of the process, the latter, with its 
associated elaboration of collagenase, may be a 
dominant factor in the tissue destruction seen 
with protracted inflammation (5). It would 
therefore be of interest to determine whether 
antirheumatic drugs interfere with connective 
tissue activation, a possibly essential step in the 
connective tissue contribution to the inflamma- 
tory process. Preliminary work reported by 
this (6-8) and other (9) laboratories suggests 
that cortisol and other antirheumatic drugs may 
modify connective tissue activation in vitro. 
This report deals in a more comprehensive 
manner with a wider range of drugs and ap- 
proaches certain aspects of their mode of action. 
MATERIALS AND METHODS 
Tissue Culture Metho&. Culture methods have been 
described in detail earlier (10-12). Synovial tissue was ob- 
tained at amputation or arthrotomy and dissected into 1 x 2 
mm explants which were immobilized under perforated 
cellophane in T-9 or T-15 flasks. T h e  synovial cell strains 
developed for this study came from normal joints and pa- 
tients with degenerative joint disease or traumatic synovitis. 
Routine culture medium consisted of medium 1066 (go%), 
fetal calf serum (10%) and heat-inactivated human serum 
(10%) supplemented with 100 pg each of penicillin G and 
streptomycin sulfate, as well as 0.002 mM L-glutamine. 
Nutrient medium was changed completely every 48 to 72 
hours. When sufficient outgrowth of fibroblastic cells had 
occurred, it was dispersed with 0.1% trypsin and used to 
initiate monolayer cultures in serum dilution bottles. Cell 
dispersion was accomplished with crystalline trypsin,* 1 .O 
mg/ml, and enumeration was carried out with a Coulter 
Model B electronic cell counter. Aliquots of explant ma- 
terial and dispersed cells were stored by freezing with 6 F  
dimethylsulfoxide (DMSO), as noted earlier (12). T o  avoid 
the unpredictable behavior of senescent cell strains, we re- 
stricted use of cell strains to the first ten trypsin subcultcres 
following derivation from primary explants. 
~~~~ 
*Worthingon Biochemical Corporation, Freehold, New 
Jersey. 
Chemicol Measurements. Hyaluronic acid was mea- 
sured in both serum-containing (13) and serum-free media 
(1) by methods involving isolation of the polymer followed 
by determination of the uronic acid moiety with a modified 
carbazole procedure (14). Glucose was measured by a 
glucose oxidase method (15) and lactate by the Barker- 
Summerson procedure (16). Protein was determined by the 
method of Oyama and Eagle (1  7). 
Preparation of Connective Tissue Activating Pep- 
tide. Except where otherwise indicated, the C T A P  used in 
these experiments was prepared from human spleen by 
homogenizing the tissue in 10 volumes of buffer containinq 
0.15 M sodium chloride, 0.05 M phosphate buffer, pH 7. 
and 0.1% 8-mercaptoethanol. Following homogenization 
of splenic tissue in a Waring blender, the mixture was 
stirred for several hours at 4” C and gross particulate ma- 
terial removed by centrifugation at 5” C. T h e  supernatant 
fraction was applied to a Sephadex G-50 column, and a 
broad zone of retained material was collected and the vol- 
ume reduced by rotary evaporation at 30’C. This was 
dialyzed against buffered saline containing 0.0005 M cys- 
teine and the volume adjusted so that 1.0 ml of extract 
represented I .0 R of the oriqinal splenic tissue. 
Antirheumotk Drugs. Antirheumatic agents included 
flufenamic acid (Lot No. X9063), mefenamic arid (X8726) 
and meclofenamic acid (X40590), supplied by Parke, Davis 
and Co. Indomethacin (L590266-0-70) and aurothiomalate 
(L413984-01A17) were provided by Merck Sharp & Dohme 
Research Laboratories. Phenylbutazone (SNI 5064) was a 
gift of the Geigy Corporation. Chloroquine diphosphate 
(N37458) and hydroxychloroquine sulfate (N069RK) were 
obtained from the Winthrop Laboratories. 
Esperimentol Protocols. Most of the experiments 
utilized the  procedure previously outlined for the 
measurement of C T A P  activity (1). In general, cultures 
were set out with 1 x 10 normal synovial fibroblasts per 
T-15 flask in a serum-containing medium. After a 4- to 6-  
hour interval to allow cell attachment to the glass, the ser- 
um-containing medium was removed and replaced by an 
assay medium consisting of Eagle’s synthetic medium 
buffered with HEPES buffer.* A typical experiment would 
include 4 groups of flasks: Group 1 including control cells 
treated with a vehicle; Group 2, cells treated with test 
drugs; Group 3, cells treated with C T A P  sufficient to in- 
duce a high level of activation; and Group 4, cells treated 
with C T A P  and antirheumatic drugs whose eficary as a 
blocker of “activation” was under test. Unless otherwise 
noted, the CTAP and drugs were added simultaneously. 
*N-2-Hydroxyethylpiperazine-N‘-2-ethanesulfonic acid, 
from Calbiochem, Los Angeles, California. 
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Table 1. Failure of Colchicine and Chloroquine to Impede the Activation Process* 
Assay Glucose uptake Lactate output HAt synthesis Reduction of 
cell (pM/mg cell (pM/mg cell rate (pg HA/mg Incremental HA incremental 
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2.0 p g h l  
diphosphate. 
























- - 6.6 
(4.6-8.5) 
124.7 118.1 - 
(1 20.4-1 29.1) 
- - 8.2 
(6.7-10.6) 
119.9 111.7 5 
(1 17.1-124.8) 
- - 3.71 7.2 
(3.26-4.07) (5.9-8.2) 
13.38 128.1 120.9 0 
(12.48-14.1 1) (120.2-132.2) 
*The data are recorded as the mean of triplicate determinations, and the range is shown in  
tHA=hyaluronic acid 
parentheses. The assay medium did not include serum. 
Usually, culture groups were planted in triplicate; and the 
data appearing in the tables are the mean of the observa- 
tions, while the ranges of the observations appear in pa- 
rentheses. Activation of a connective tissue cell strain is 
reflected by a marked increase in the hyaluronic acid syn- 
thesis rate measured as incremental hyaluronic acid per ml: 
cell of protein per 24 hours of incuhation time. Drugs which 
effectively interfere with the activation process reduced the 
incremental hyaluronate synthesis induced by CTAP. 
RESULTS 
Colchicine and Chloroquine. Colchicine 
added to synovial cultures in a concentration of 
1.0 pg/ml failed tn impede the activation proc- 
ess stimulated by a simultaneously introduced 
C T A P  preparation (Table I ) .  T h e  concentra- 
tion of colchicine employed was ample to pro- 
duce metaphase arrest in cultivated synovial 
cells and is in excess of plasma concentrations 
achieved during therapy with this agent in 
humans. Not only was the burst of hyaluronate 
formation du r ing  t h e  activation process 
unaffected by the presence of colchicine, but 
accelerated glucose uptake and lactate output 
were also unaffected. In a similar experiment, 
ch loroquine  d iphosphate ,  2.0 p g l m l ,  was 
shown to be without significant effect on the 
activation process (Table 1). T h e  last column of 
Table 1 indicates that the added drugs did little 
to reduce the incremental hyaluronate synthesis 
incident to activation. T h e  chloroquine di- 
phosphate concentration, although greater than 
that achieved in human patients treated with 
this agent (1 8), produced no obvious morpho- 
logic alterations in the synovial cells which could 
he visualized by the light microscope in the liv- 
ing cultures. This latter observation contrasts 
with the situation with colchicine-treated cul- 
tures where the cells exhibited marked round- 
ing. 
Aurothiomalate and Phenylbutazone. 
T h e  addition of aurothiomalate (1.0 to 6.0 pg/ 
ml of culture medium) failed to depress the ac- 
celerated uptake of glucose, enhanced lactate 
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Table 2. Effect of Gold and Phenylbutarone on Connective Tissue Activation* 
~~~ ~~ 
Assay Glucose uptake Lactate output H A t  synthesis Reduction of 
cell (pM/mg cell ( rM/rng cell rate (pg HA/mg Incremental HA incremental 





































- 5.6 - 
(4.2-7.9) 
31.6 26.0 - 
(24.9-35.2) 
- - 6.1 
(4.9-7.1) 
35.6 29.5 0 
32.0 25.9 0 




*The assay medium did not include serum. 
+HA= hyaluronic acid 
SAurothiomaIate 
output and increased hyaluronate synthesis in- 
cident to addition of CTAP to test cultures 
(Table 2). These concentrations include and 
exceed those found in rheumatoid patients 
treated by chrysotherapy (19). O n  the other 
hand, it is clear from Table 2 that phenylbuta- 
zone substantially depresses all of the measured 
parameters of connective tissue cell activation at 
concentrations effective in clinical usage (20). 
Salicylates, Hydroxychloroquine, In- 
domethacin and Cortisol. Many of the 
commonly used antirheumatic drugs were test- 
ed simultaneously in CTAP-activated synovial 
cell cultures with the results illustrated in Table 
3. This experiment provided evidence for strong 
inhibition of the activation process by acetyl- 
salicylic acid, indomethacin, phenylbutazone 
and cortisol. On the other hand, hydroxychlo- 
roquine and sodium salicylate appeared to be 
without suppressive effect. Salicylates (21), in- 
domethacin (22) and phenylbutazone (20) were 
added in concentrations approximating those 
achieved in the plasma of patients undergoing 
t rea tment  with these agents, while hy- 
droxychloroquine (18) was used in a supra- 
therapeutic concentration. 
Effect of Serum on the Action of An- 
tirheumatic Drugs. T o  assess the possibility 
that serum proteins might significantly alter the 
action of the antirheumatic drugs, parallel as- 
says were performed in which one group of 
flasks was studied using the usual serum-free 
media, while a second group included 10% fetal 
calf serum and 10% human serum. It was clear 
that for the potent drugs such as indomethacin, 
phenylbutazone, acetylsalicylic acid and cor- 
tisol, serum does partially block the suppressive 
effects of the antirheumatic drugs. As noted in 
F igure  1, hydroxychloroquine and  sodium 
salicylate have very little suppressive action re- 
gardless of whether serum is present. 
Dose-Response Studies. The  ability of 
cortisol in a serum-free assay system to suppress 
synovial cell activation was studied over a con- 
centration range from 0.005 to 1.0 pg/ml. As 
shown in Figure 2, there was a significant sup- 
pression of synovial cell activation at the lowest 
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Table 3. Effect of Antirheumatic Drugs on Activation in Absence of Serum 
Assay Glucose uptake Lactate output HA synthesis Reduction of 
cell Drug added CTAP (pM/mg cell (pM/mg cell rate (pg HA/mg incremental 
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concentration used, with very little additional 
suppression above 0.05 pg/ml. In a similar 
study carried out in the presence of serum, clear 
suppression of activation was noted at 0.05 pg 
cortisol/ml, and peak suppression occurred at 
about 1.0 pg/ml. These data are of particular 
interest since the biologic regulatory action oc- 
curs at physiologic steroid concentrations (23). 
Synovial fluid from rheumatoid patients con- 
tained 0.07 pg 17-hydroxy-corticosteroids/ml 
of fluid, of which 0.008 pg/ml was unbound 
cortisol (23). 
Dose-response studies for a group of non- 
steroidal antirheumatic drugs are shown in 
Figure 3. It is clear from this study that in- 
domethacin and meclofenamic acid suppress 
activation in very low concentrations, whereas 
s u b s  t a n t i a 11 y h i g h e r  c o n c e n t r a t i o n s  of 
phenylbutazone and sodium salicylate were 
required for suppression in this particular as- 
say. It appeared that once an optimal drug 
concentration had been reached, further in- 
crease in concentration led to no additional 
suppression of activation. 
Direct Exposure of CTAP to Antirheu- 
matic Drugs. The  possibility that an- 
tirheumatic drugs might actually alter the 
CTAP added simultaneously to the assay cul- 
ture was examined by incubating various agents 
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Fig 1. Suppression of connective tissue activation by antirheumatic drugs; the effect of serum. 
Hydroxychloroquine and sodium salicylate show little antiactivation capacity, and serum de- 
presses that capacity for the more potent agents. 
with CTAP for 4 hours at 37" C and then re- 
moving the drug by dialysis for 16 hours at 6" C .  
As shown in Table 4, there was little convincing 
evidence that direct exposure of CTAP to these 
drugs resulted in alteration of the activation 
capacity of the CTAP, particularly in the case 
of cortisol, hydroxychloroquine and acetylsali- 
cylic acid. While it is possible that indometha- 
cin and phenylbutazone ma): have actually pro- 
duced partial alteration of CTAP, we did not 
rule out the possibility that some of the drugs 
may have remained bound to CTAP and were 
carried into the assay culture, thus causing the 
minimal reduction in CTAP activity shown in 
Table 4. 
The Eflect of Time of Drug Exposure on 
the Antiactivation Eflect. It may be seen 
from Table 5 that most antirheumatic drugs 
were equally effective if given at either zero 
time or 2 hours after CTAP was added to the 
assay cultures. Several drugs were ineffective if 
-100 r ae m 0 - V 
Fig 2. Cortisol suppression of synovial 
cell activation; dose-response study. 
Regulation of synovial cell activation 
centrations. 
I rl I 
occurs at physiologic cortisol con- 0 0.05 0.10 1.00 
Cortisol, M/ml  of Serum-Free Media 
Arthritis and Rheumatism, Vol. 15, No. 5 (September-October 1972) 509 
CASTOR 
h 100 - 0....0 
$ 
0)  Phenylbutazone 
v 
lndornethacin 







0 ;  
s 20 




L .  
a '  
.C.C*-* 
D 
0 10 20 30 40 50 ' 100 200 300 
Drug Concentration, Fg/ml of Serum-Free Media 
Table 4. Drug Alteration of CTAP 
~ 
Drug exposure* Activation induced by 
(pg/ml) drug-exposed CTAP (70) 
None 100 
Cortisol, 1.0 100 
Hydroxychloroquine, 2.0 92 
Sodium salicylate. 150.0 87 
Indomethacin. 15.0 62 
Phenylbutazone. 75.0 73 
Acetylsalicylic acid, 300.0 100 
*Drug + CTAP incubated 4 hours at 37°C then 
dialyzed 16 hours at 6°C. 
added as late as 8 hours after CTAP, and very 
few had a measurable effect on the activation 
process if given 24 hours after CTAP stimula- 
tion of the cultures-ie, after the activation se- 
quence was fully established. 
DISCUSSION 
Conceptualization of antiinflammatory drug 
action is made difficult by the complexity of the 
inflammatory process (depicted schematically in 
Figure 4). Acute inflammation embraces the 
phenomena associated with alterations of the 
microcirculation, the exudative process and tis- 
sue destruction associated with anoxia or the 
release of lysosomal enzymes. The  dominant 
Fig 3. Effect of nonsteroidal 
agents on connective tissue activa- 
tion; dose-response study. Non- 
steroidal agents tend to  show maxi- 
mal antiactivation activity at 
concentrations similar t o  those 
achieved in clinical use. 
cells in this early reaction are largely derived 
from the leukocytes of the circulating blood. 
Chronic inflammation includes the prolifera- 
tive (reparative or destructive) reaction, pre- 
dominantly reflecting the performance (or mal- 
function) of connective tissue cells. It is clear 
from Figure 4 that several pathways lead to the 
adverse functional and anatomic changes result- 
ing from chronic inflammation. A particular an- 
tiinflammatory agent may exert no inhibitory 
capacity on some pathways, and show a range 
of suppressive ability against the others. In this 
context, the performance of a drug against 
chronic inflammation would depend not only on 
how effectively it inhibited particular path- 
ways, but also on the relative importance of the 
different pathways to the perpetuation of the 
injammatory process in a given clinical situa- 
tion. We presently have no satisfactory methods 
for weighing the importance of the different 
components of the inflammatory process out- 
lined in Figure 4, either in terms of their 
proportional contributions to tissue dysfunction 
or destruction, or even their essentiality to the 
self-perpetuating character of chronic inflam- 
mation. 
The  present study examines the in  vitro ac- 
tion of several antirheumatic drugs against a 
portion of the connective tissue component of 
the inflammatory process and may provide a 
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Table 5. Time of Drug Exposure: Effect on Activation 














rO hr 72 hr 7i hr 724 hr 
Transcription 
’ Translation Specific 
Conc product 
P
for mat ion (pg/ml) 
4.0 100 100 100 59 
80.0 100 100 100 73 
5.0 65 75 0 0 
75.0 100 100 66 65 
75.0 82 82 43 0 
15.0 53 64 0 0 
2.0 28 25 0 0 
150.0 38 60 15 0 
150.0 63 63 0 0 
1 .o 85 80 58 0 
1 .o 89 71  67 0 
-7 indicates the number of hours following addition of CTAP to  cultures when a particular anti- 
rheumatic agent was added The arrows under Trarncrip/iorr. Trando/rmrr and Sprrrfii p r id / r ( /  
/ormalion are meant to convey, in  a schematic fashion. an impression of the temporal sequence and 
duration of these processes 
+Assay strain = HH 
$Assay strain = ArM 




I, Energy Metabolism 
2. Cel I Proliferation 
3 MPS Formation 
5 Enzymatic “Remodelinf----LC 
4, Collagen Desposition *e*” -
HEALED SCAR 
Fig4. A schematic diagram of the interrelationship of major systems involved in the chronic 
inflammatory reaction 
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novel insight into their mechanism of action. 
Earlier studies indicated that the biosynthesis of 
connective tissue ground substance components 
was modified by antirheumatic drugs. Both 
corticosteroid and nonsteroid antiinflammatory 
drugs have been reported to depress t h e  
biosynthesis of sulfated mucopolysaccharides in 
cartilage, cornea and heart valve (24, 25). 
Other data suggest that blockade of sulfate in- 
corporation in these tissues might be the major 
drug action rather than inhibition of macromol- 
ecule biosynthesis (26). Glucocorticoids sup- 
press formation of hyaluronate (a nonsulfated 
mucopolysaccharide) by approximately 50% in 
human synovial cells studied in a basal (ie, 
nonactivated) state in tissue culture (27, 28). A 
recent report from this laboratory indicated 
that indomethacin caused a minor, equivocal 
depression of hyaluronate formation in basal 
synovial cultures, and phenylbutazone caused a 
definite, but minor, reduction in hyaluronate 
formation (29). 
From Table 3 it is clear that hydroxychlo- 
roquine, sodium salicylate, acetylsalicylic acid, 
indomethacin and phenylbutazone exert virtu- 
ally no depressive effect on the basal hyalu- 
ronic acid synthesis rate of human synovial 
cells. In other experiments meclofenamate (5.0 
rcg/ml) did not depress basal hyaluronic acid 
synthesis. It is interesting that cortisol sup- 
pression of basal hyaluronic acid synthesis by 
synovial cultures is most consistently demon- 
strated in the presence of serum-containing 
media. On the other hand, when human syno- 
vial cells are activated, exposure to cortico- 
steroids and most of the nonsteroidal 
antiinflammatory drugs results in marked sup- 
pression of incremental hyaluronic acid syn- 
thesis. These observations suggest that the ma- 
jor role of antirheumatic drugs in reducing 
synovial hyaluronate synthesis in pathologic 
states may not be related primarily to interjer- 
ence with polymer synthesis per se, but instead 
to  interdiction ofsynovial cell activation. 
In studies reported elsewhere (30), it was 
demonstrated that synovial cell activation was 
independent of DNA synthesis, but required 
DNA-mediated RNA synthesis and protein 
synthesis. Inhibitors of transcription (actino- 
mycin D, mithramycin, acidine orange, chro- 
momycin A3 and a-amanitin) and translation 
(puromycin, cycloheximide and acetoxycyclo- 
heximide) all blocked the activation process if 
added to cultures simultaneously with CTAP. 
Inhibition of transcription 4 hours after addi- 
tion of CTAP produced no inhibition of activa- 
tion, and, similarly, interference with protein 
synthesis 16 hours or more following an activat- 
ing stimulus was without inhibitory effect on 
the activation process. In the context of these 
observations it was interesting to note that the 
efficacy of those antirheumatic drugs showing 
an antiactivation effect was closely tied to the 
timing of drug administration in relation to the 
activating event (addition of CTAP). The an- 
tirheumatic drugs were most effective if added 
to cultures simultaneously with CTAP or 2 
hours later, early enough to interfere with the 
transcription component of the activation proc- 
ess. Drugs added 8 hours after the activating 
event (during translation) frequently showed 
reduced efficacy in blocking activation, al- 
though substantial suppression was usually 
demonstrable. If 24 hours elapsed after an ac- 
tivating event, most of the antirheumatic drugs 
were without effect. Drugs suppressing hyalu- 
ronic acid synthesis in fully activated cells (24 
hours post-CTAP) presumably would act on 
the polymer synthesizing mechanism itself. 
Both flufenamic and mefenamic acid partially 
suppressed incremental hyaluronic acid syn- 
thesis in fully activated cells. The  possibility of 
individual cell strain differences in drug sensi- 
tivity was raised by the experiments with 
phenylbutazone where incremental hyaluronic 
acid synthesis was substantially suppressed in 
fully activated “HH” cells but not in the 
“ArM” strain. In summary, the in vitro evi- 
dence suggests that antirheumatic drugs sup- 
press hyaluronate synthesis by synovial cells 
primarily by interfering with the activation se- 
quence. Further, the time-related experiments 
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are consonant with the possibility that the 
eflective drugs act mainly on the transcriptional 
and translational component of the activation 
sequence. 
Salicylates, the anthranilic acid derivatives, 
phenylbutazone and indomethacin are known 
to be capable of uncoupling oxidative phos- 
phorylation in mammalian cells (24), and it has 
been suggested that these drugs may antagonize 
the inflammatory process by denying adenosine 
triphosphate to energy-dependent components 
of the process. T h e  drug concentrations used 
here (which mimic those attainable clinically) 
failed to stimulate glucose uptake or lactate 
formation. These phenomena are demonstrable 
when synovial cells are exposed to 4 x 10 -j M 
2,4-dinitrophenol, an  agent whose major action 
is uncoupling of oxidative phosphoryla- 
tion (31). This is indirect evidence that uncou- 
pling of oxidative phosphorylation is not a sig- 
nificant factor in antirheumatic drug blockade 
of activation. 
Dose-response studies carried out in a tissue 
culture system may provide information rele- 
vant to extracellular fluid drug concentrations 
required to modify cell function. It was interest- 
ing to note that phenylbutazone and sodium 
salicylate interfered maximally with the activa- 
tion process at concentrations similar to those 
achieved in the blood of patients treated with 
these agents. Indomethacin, on the other hand, 
blocked activation in concentrations well below 
those seen in clinical situations. Cortisol, tested 
in serum-free medium, exhibited marked anti- 
activation capabilities even at physiologic con- 
centrations, but higher concentrations were 
required when serum was present. In this in 
vitro test situation, serum proteins clearly re- 
duced the antiactivation effects of indometha- 
cin, phenylbutazone, acetylsalicylic acid and 
cortisol by amounts ranging from 20.0 to 60.0% 
of the values noted in a serum-free environ- 
ment. In intact man these agents are known to 
be bound to plasma proteins, a phenomenon 
important to the extent that it dictates avail- 
ability of drug to target cells. 
It was not surprising to find that gold salts 
and antimalarial drugs, known for their delayed 
onset of action against rheumatoid inflamma- 
tions, had little or no activity against the ac- 
tivation process. These agents may modify the 
kinetics of lysosomes and/or their enzymatic 
contents, possibly interfering directly with some 
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